Package Leaflet: Information for the User
Telmisartan/Hydrochlorothiazide Teva-ratio 80 mg/12.5 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Telmisartan/Hydrochlorothiazide Teva-ratio is a combination of two active substances, telmisartan and hydrochlorothiazide, in one tablet. Both active substances help to control high blood pressure.
Telmisartan blocks the effect of angiotensin II, causing the blood vessels to relax and your blood pressure to decrease.
High blood pressure, if left untreated, can damage blood vessels in various organs, which can sometimes lead to heart attack, heart failure, kidney failure, stroke, or blindness. Usually, there are no symptoms of high blood pressure before damage occurs. Therefore, it is important to regularly check your blood pressure to ensure it is within the normal range.
Telmisartan/Hydrochlorothiazide Teva-ratio is usedfor the treatment of high blood pressure (essential hypertension) in adults whose blood pressure is not adequately controlled with telmisartan alone.
Do not take Telmisartan/Hydrochlorothiazide Teva-ratio
If any of the above applies to you, tell your doctor or pharmacist before taking Telmisartan/Hydrochlorothiazide.
Warnings and precautions
Consult your doctor before starting to take Telmisartan/Hydrochlorothiazide if you have or have had any of the following conditions or diseases:
Consult your doctor before starting to take Telmisartan/Hydrochlorothiazide:
Your doctor may need to check your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals. See also the information under the heading "Do not take Telmisartan/Hydrochlorothiazide Teva-ratio".
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking telmisartan/hydrochlorothiazide. Your doctor will decide whether to continue treatment. Do not stop taking telmisartan/hydrochlorothiazide.
If you are pregnant, think you may be pregnant, or are planning to become pregnant, inform your doctor. Telmisartan/Hydrochlorothiazide is not recommended during the first trimester of pregnancy (first 3 months) and should not be taken after the third month of pregnancy as it may cause serious harm to your baby, see section Pregnancy.
Treatment with hydrochlorothiazide can cause an electrolyte imbalance in your body. Typical symptoms of fluid or electrolyte imbalance include dry mouth, weakness, lethargy, somnolence, restlessness, pain or muscle cramps, nausea, vomiting, muscle fatigue, and an abnormally rapid heart rate (more than 100 beats per minute). If you experience any of these symptoms, inform your doctor.
You should also inform your doctor if you experience increased sensitivity of your skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) that appear more quickly than usual.
If you are going to undergo surgery or anesthesia, inform your doctor that you are taking Telmisartan/Hydrochlorothiazide.
Telmisartan/Hydrochlorothiazide may be less effective in lowering blood pressure in black patients.
Children and adolescents
Telmisartan/Hydrochlorothiazide is not recommended for use in children and adolescents up to 18 years of age.
Use in athletes
This medicine contains hydrochlorothiazide, which may produce a positive result in doping tests.
Other medicines and Telmisartan/Hydrochlorothiazide Teva-ratio
Inform your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Your doctor may need to change the dose of those other medicines or take other precautions. In some cases, it may be necessary to stop using one of these medicines, especially if you are using any of the following medicines with Telmisartan/Hydrochlorothiazide:
Telmisartan/Hydrochlorothiazide may increase the effect of other medicines to lower blood pressure or medicines that may potentially lower blood pressure (e.g., baclofen, amifostine). Additionally, the decrease in blood pressure may be increased by alcohol, barbiturates, narcotics, or antidepressants. You may notice this effect as dizziness when standing up. You should inform your doctor about the need to adjust the dose of your other medicines while taking Telmisartan/Hydrochlorothiazide.
The effect of Telmisartan/Hydrochlorothiazide may be reduced when using non-steroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin or ibuprofen).
Taking Telmisartan/Hydrochlorothiazide with food and alcohol
You can take this medicine with or without food.
Avoid drinking alcohol until you have talked to your doctor. Alcohol can further lower your blood pressure and/or increase the risk of feeling dizzy or weak.
Pregnancy and breastfeeding
Pregnancy
You should inform your doctor if you are pregnant, think you may be pregnant, or are planning to become pregnant. Your doctor will normally advise you to stop taking Telmisartan/Hydrochlorothiazide before you become pregnant or as soon as you find out you are pregnant, and will recommend that you take a different blood pressure medicine instead. Telmisartan/Hydrochlorothiazide is not recommended during pregnancy and should not be taken after the third month of pregnancy as it may cause serious harm to your baby.
Breastfeeding
Inform your doctor if you are about to start or are breastfeeding, as Telmisartan/Hydrochlorothiazide is not recommended for use during breastfeeding. Your doctor may decide to prescribe a treatment that is more suitable if you want to breastfeed.
Driving and using machines
Some patients feel dizzy or tired when taking Telmisartan/Hydrochlorothiazide. If you feel dizzy or tired, do not drive or use machines.
Telmisartan/Hydrochlorothiazide Teva-ratio contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per film-coated tablet; this is essentially "sodium-free".
The recommended dose is one tablet per day. Try to take one tablet each day at the same time. You can take Telmisartan/Hydrochlorothiazide with or without food. The tablets should be swallowed with a little water or another non-alcoholic drink. It is important that you take Telmisartan/Hydrochlorothiazide every day until your doctor tells you to stop.
If your liver is not working properly, the usual dose should not exceed 40 mg/12.5 mg once daily.
If you take more Telmisartan/Hydrochlorothiazide Teva-ratio than you should
If you accidentally take too many tablets, you may experience symptoms such as low blood pressure and rapid heartbeat. Slow heartbeat, dizziness, vomiting, and reduced kidney function, including kidney failure, have also been reported. Due to the hydrochlorothiazide component, you may also experience significantly low blood pressure and low potassium levels in the blood, which can lead to nausea, somnolence, and muscle cramps and/or irregular heartbeat associated with concomitant use of medicines like digitalis or certain antiarrhythmic treatments. Contact your doctor or pharmacist or the nearest hospital emergency department immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Telmisartan/Hydrochlorothiazide Teva-ratio
If you forget to take your medicine, do not worry. Take the dose as soon as you remember and continue as before. If you do not take your tablet one day, take your normal dose the next day. Do not take a double dose to make up for forgotten doses.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Some adverse effects can be serious and require immediate medical attention:
If you experience any of the following symptoms, you should visit your doctor immediately:
Sepsis* (often called "blood infection"), is a serious infection that involves an inflammatory reaction of the entire body, rapid swelling of the skin and mucous membranes (angioedema), blistering and peeling of the outer layer of the skin (toxic epidermal necrolysis); these adverse effects are rare (may affect up to 1 in 1,000 people) but are extremely serious and patients should stop taking the medicine and visit their doctor immediately. If these adverse effects are not treated, they can be fatal. An increase in the incidence of sepsis has been observed with telmisartan alone; however, it cannot be ruled out for Telmisartan/Hydrochlorothiazide.
Possible Adverse Effects of Telmisartan/Hydrochlorothiazide Teva-ratio:
Frequent Adverse Effects(may affect up to 1 in 10 people)
Dizziness.
Infrequent Adverse Effects(may affect up to 1 in 100 people)
Decrease in potassium levels in the blood, anxiety, fainting (syncope), tingling sensation, numbness (paresthesia), dizziness (vertigo), rapid heartbeats (tachycardia), heart rhythm disturbances, low blood pressure, sudden drop in blood pressure when standing up, shortness of breath (dyspnea), diarrhea, dry mouth, flatulence, back pain, muscle spasms, muscle pain, erectile dysfunction (inability to have or maintain an erection), chest pain, and increased uric acid levels in the blood.
Rare Adverse Effects(may affect up to 1 in 1,000 people)
Lung inflammation (bronchitis), activation or worsening of systemic lupus erythematosus (a disease in which the body's immune system attacks the body itself, causing joint pain, skin rashes, and fever), sore throat, sinus inflammation, feeling of sadness (depression), difficulty falling asleep (insomnia), vision disturbance, breathing difficulties, abdominal pain, constipation, abdominal distension (dyspepsia), general malaise (vomiting), stomach inflammation (gastritis), alteration in liver function (Japanese patients show a greater tendency to experience this adverse effect), skin redness (erythema), allergic reactions such as itching or rash, increased sweating, hives (urticaria), joint pain (arthralgia), and pain in the limbs, muscle cramps, pseudogrippal illness, pain, low sodium levels, increased creatinine, liver enzymes, or creatine phosphokinase levels in the blood.
Very rare adverse effects (may affect up to 1 in 10,000 people):
Acute respiratory distress (symptoms include severe respiratory distress, fever, weakness, and confusion).
Adverse reactions reported for one of the individual components may be potential adverse reactions of Telmisartan/Hydrochlorothiazide, although they have not been observed in clinical trials with this product.
Telmisartan
The following additional adverse effects have been described in patients taking telmisartan alone:
Infrequent Adverse Effects(may affect up to 1 in 100 people):
Upper respiratory tract infection (e.g., sore throat, sinus inflammation, common cold), urinary tract infections, red blood cell deficiency (anemia), high potassium levels, slow heart rate (bradycardia), cough, alteration in kidney function including acute kidney failure, weakness.
Rare Adverse Effects(may affect up to 1 in 1,000 people):
Low platelet count (thrombocytopenia), increased white blood cell count (eosinophilia), severe allergic reactions (e.g., hypersensitivity, anaphylactic reactions, drug rash), low blood sugar levels (in diabetic patients), drowsiness, stomach discomfort, eczema (a skin disorder), osteoarthritis, tendon inflammation, decreased hemoglobin (a blood protein).
Very Rare Adverse Effects(may affect up to 1 in 10,000 people)
Progressive lung tissue fibrosis (interstitial lung disease) **
Frequency Not Known(cannot be estimated from available data):
Intestinal angioedema: inflammation in the intestine with symptoms such as abdominal pain, nausea, vomiting, and diarrhea has been reported after the use of similar products.
** Cases of progressive lung tissue fibrosis have been reported during the use of telmisartan. However, it is unknown whether telmisartan was the cause.
Hydrochlorothiazide
The following additional adverse effects have been described in patients taking hydrochlorothiazide alone:
Frequent Adverse Effects(may affect up to 1 in 10 people)
Nausea, low magnesium levels in the blood.
Rare Adverse Effects(may affect up to 1 in 1,000 people)
Decrease in blood platelets, which increases the risk of bleeding and bruising (small purple-red marks on the skin or other tissues caused by bleeding), high calcium levels in the blood, headache.
Very Rare Adverse Effects(may affect up to 1 in 10,000 people)
Increased pH (alteration of acid-base balance) due to low chloride levels in the blood.
Frequency Not Known(cannot be estimated from available data)
Salivary gland inflammation, skin and lip cancer (non-melanoma skin cancer), decrease in blood cell count, including low red and white blood cell count, severe allergic reactions (e.g., hypersensitivity, anaphylactic reactions), decreased or lost appetite, restlessness, dizziness, blurred or yellowish vision, decreased vision, and eye pain [possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma], blood vessel inflammation (necrotizing vasculitis), pancreas inflammation, stomach discomfort, yellowing of the skin or eyes (jaundice), pseudolupus syndrome (a condition that mimics systemic lupus erythematosus), skin disorders such as skin blood vessel inflammation, increased sensitivity to sunlight, skin rash, skin redness, lip blistering, eye or mouth blistering, skin peeling, fever (possible signs of erythema multiforme), weakness, kidney inflammation or altered function, glucose in the urine (glucosuria), fever, altered electrolyte balance, high cholesterol levels in the blood, decreased blood volume, increased blood sugar levels, difficulty controlling blood sugar levels/urine in patients with a diagnosis of diabetes mellitus, or fat in the blood.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that does not appear in this leaflet.
You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton after "EXP". The expiration date is the last day of the month indicated.
For Al/Al blisters
This medicine does not require special storage conditions.
For Al/PVC/PVDC blisters
Do not store above 30°C.
Medicines should not be disposed of via wastewater or household waste. Place the packaging and any unused medicines in the SIGRE collection point at your usual pharmacy. Ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Composition of Telmisartan/Hydrochlorothiazide Teva-ratio
The active ingredients are telmisartan and hydrochlorothiazide. Each tablet contains 80 mg of telmisartan and 12.5 mg of hydrochlorothiazide.
The other ingredients are magnesium stearate, meglumine, microcrystalline cellulose, povidone, potassium hydroxide, sodium starch glycolate (type A), and mannitol (E421).
Appearance of the Product and Package Contents
Telmisartan/Hydrochlorothiazide Teva-ratio 80 mg/12.5 mg tablets are capsule-shaped, 9.0 x 17.0 mm with TH 12.5 engraved on both sides.
Package sizes
Blister: 28 tablets
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Teva Pharma, S.L.U.
C/ Anabel Segura, 11. Edificio Albatros B, 1ª planta
28108 Alcobendas, Madrid
Spain
Manufacturer
Actavis ehf.
Reykjavíkurvegur 78
IS220
Hafnarfjördur
Iceland
Ó
Actavis Ltd.
BLB016
Bulebel Industrial Estate
Zejtun ZTN 3000 Malta
Date of Last Revision of this Leaflet: March 2025
Other Sources of Information
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
You can access detailed and updated information about this medicine by scanning the QR code included in the packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/79608/P_79608.html
QR Code + URL
The average price of TELMISARTAN/HYDROCHLOROTHIAZIDE TEVA-RATIO 80 mg/12.5 mg TABLETS in October, 2025 is around 19.36 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.